Cytokines: Interleukins and tumournecrosis factor - Pharmaceutical Biotechnology: Concepts and Aapplications - page 264

Further reading
Books
Balkwill, F. 2000. The Cytokine Network . Oxford University Press.
Fitzgerald, K.A., O'Neill, L.A.J., Gearing, A.J.H., and Callard, RE. 2001. The Cytokine Factsbook . Academic
Press.
Mantovani, A. 2000. Pharmacology of Cytokines . Oxford University Press.
Moreland, L. and Emery, P. (eds). 2003. TNF -α Inhibition in the Treatment of Rheumatoid Arthritis . Taylor and
Francis, London.
Mire-Sluis, A. 1998. Cytokines . Academic Press.
Thompson, A. (ed.). 2003. The Cytokine Handbook . Academic Press, London.
Articles
Interleukins
Atkins, M. 2002. Interleukin 2: clinical applications. Seminars in Oncology 29 (3), 12-17.
Aulitzky, W.E., Schuler, M., Peschel, C., and Huber, C. 1994. Interleukins. Clinical pharmacology and therapeutic
use. Drugs 48 (5), 667-677.
Brown, M. and Hural, J. 1997. Function of IL-4 and control of its expression. Critical Reviews in Immunology
17 (1), 1-32.
Devos, R., Plaetinck, G., Cornelis, S., Guisez, Y., Van der Heyden, J., and Tavernier, J. 1995. Interleukin-5 and its
receptor: a drug target for eosinophilia associated with chronic allergic disease. Journal of Leukocyte Biology
57 , 813-818.
Fehniger, T.A., Cooper, M.A., and Caligiuri, M.A. 2002. Interleukin-2 and interleukin-15: immunotherapy for
cancer. Cytokine and Growth Factor Reviews 13 (2), 169-183.
Fickenscher, H., Hor, S., Kupers, H., Knappe, A., Wittmann, S., and Sticht, H. 2002. The interleukin-10 family of
cytokines. Tren ds in Im mu nology 23 (2), 89-96.
Fry, J. and Mackall, C. 2002. Interleukin-7: from bench to clinic. Blood 99 (11), 3892-3904.
Hawrylowich, C. and O'Garra, A. 2005. Potential role of interleukin-10 secreting regulatory T-cells in allergy and
asthma. Nature Reviews Immunology 5 (4), 271-283.
Hohlfeld, R. 1997. Biotechnological agents for the immunotherapy of multiple sclerosis - principles, problems
and perspectives. Brain 120 , 865-916.
Jeal, W. and Goa, K. 1997. Aldesleukin (recombinant interleukin-2): a review of its pharmacological properties,
clinical effi cacy and tolerability in patients with renal cell carcinoma. Biodrugs 7 (4), 285-317.
Komschlies, K.L., Grzegorzewski, K.J., and Wiltrout, R.H. 1995. Diverse immunological and haematological
effects of interleukin-7: implications for clinical application. Journal of Leukocyte Biology 58 , 623-631.
Krawczenko, A., Kieda, C., and Dus, D. 2005. The biological role and potential therapeutic applications of
interleukin 7. Archivum Immunologiae et Therapiae Experimentalis 53 (6), 518-525.
Lee, Y. and Hirani, A. 2006. Interleukin-4 in atherosclerosis. Archives of Pharmacal Research 29 (1), 1-15.
Leonard, W. and Spolski, R. 2005. Interleukin 21: a modulator of lymphoid proliferation, apoptosis and
differentiation. Nature Reviews Immunology 5 (9), 688-698.
Martin, M. and Falk, W. 1997. The interleukin-1 receptor complex and interleukin-1 signal transduction. European
Cytokine Network 8 (1), 5-17.
McInnes, I. and Gracie, J. 2004. Interleukin-15: a new cytokine target for the treatment of infl ammatory diseases.
Current Opinion in Pharmacology 4 (4), 392-397.
Noble, S. and Goa, K. 1997. Aldesleukin (recombinant interleukin-2): a review of its pharmacological properties,
clinical effi cacy and tolerability in patients with metastatic melanoma. Biodrugs 7 (5), 394-422.